Quarterly ResultMay 12, 2026, 07:07 AM
Olema Q1 Net Loss $53.1M; OPERA-01 Data Expected Fall 2026
AI Summary
Olema Pharmaceuticals reported a net loss of $53.1 million for Q1 2026, an increase from $30.4 million in Q1 2025, driven by higher clinical development and research spending. The company ended the quarter with $505.3 million in cash, cash equivalents, and marketable securities. Key pipeline updates include anticipated top-line data from the Phase 3 OPERA-01 trial in fall 2026 and initial clinical data from the OP-3136 Phase 1 study to be presented at ASCO. Olema continues to enroll patients in the Phase 3 OPERA-02 trial and aims for its first commercial launch next year.
Key Highlights
- Q1 2026 net loss was $53.1 million, up from $30.4 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $505.3 million as of March 31, 2026.
- GAAP R&D expenses increased to $49.2 million in Q1 2026 from $30.6 million in Q1 2025.
- GAAP G&A expenses rose to $8.8 million in Q1 2026 from $4.2 million in Q1 2025.
- Top-line data from Phase 3 OPERA-01 trial expected in fall 2026.
- First clinical data from OP-3136 Phase 1 study to be presented at ASCO.
- Phase 3 OPERA-02 trial continues patient enrollment.
Price Impact
More from OLMA